Jeong Won Lee1, Yoo Sung Song2, Hyeyun Kim3, Bon D Ku3, Won Woo Lee2,4. 1. Department of Nuclear Medicine, Catholic Kwandong University College of Medicine, International St. Mary's Hospital, Incheon, Republic of Korea. 2. Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. 3. Department of Neurology, Catholic Kwandong University College of Medicine, International St. Mary's Hospital, Incheon, Republic of Korea. 4. Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Republic of Korea.
Abstract
BACKGROUND: To evaluate whether patients with scans without evidence of dopaminergic deficit (SWEDD) have early Parkinson's disease (PD). METHODS: The clinical characteristics, striatal specific binding ratios (SBRs), and the indices of I-123 FP-CIT SPECT images of 50 SWEDD patients, 304 PD patients, and 141 healthy controls were acquired from the Parkinson's Progression Markers Initiative (PPMI) data and evaluated during a 2-year clinical follow-up period. RESULTS: Of the 50 subjects with SWEDD, PD was confirmed in 13 subjects (the PD-SWEDD group), while the remaining 37 subjects had other diseases (the Other-SWEDD group). Striatal SBR values and striatal asymmetry indices of the PD group were significantly different with those of the PD-SWEDD and Other-SWEDD groups at both baseline and after 2 years (p < 0.001). Putaminal SBR values of the PD-SWEDD group were significantly decreased after 2 years (p < 0.05). There was no difference of the SBR values between baseline and after 2 years in the Other-SWEDD group. A baseline MDS-UPDRS III score matched comparison of the PD and PD-SWEDD group was done due to the large difference of the subject numbers. Striatal SBR values and striatal asymmetry indices were significantly different (p < 0.001) between the two groups at both baseline and after 2 years, but there were no significant difference with respect to the MDS-UPDRS III scores after 2 years between the two groups. CONCLUSION: The different SBR values and asymmetry indices between the PD and PD-SWEDD groups at baseline and after 2 years indicate that SWEDD may not be early PD, but rather a different disease entity.
BACKGROUND: To evaluate whether patients with scans without evidence of dopaminergic deficit (SWEDD) have early Parkinson's disease (PD). METHODS: The clinical characteristics, striatal specific binding ratios (SBRs), and the indices of I-123 FP-CIT SPECT images of 50 SWEDD patients, 304 PDpatients, and 141 healthy controls were acquired from the Parkinson's Progression Markers Initiative (PPMI) data and evaluated during a 2-year clinical follow-up period. RESULTS: Of the 50 subjects with SWEDD, PD was confirmed in 13 subjects (the PD-SWEDD group), while the remaining 37 subjects had other diseases (the Other-SWEDD group). Striatal SBR values and striatal asymmetry indices of the PD group were significantly different with those of the PD-SWEDD and Other-SWEDD groups at both baseline and after 2 years (p < 0.001). Putaminal SBR values of the PD-SWEDD group were significantly decreased after 2 years (p < 0.05). There was no difference of the SBR values between baseline and after 2 years in the Other-SWEDD group. A baseline MDS-UPDRS III score matched comparison of the PD and PD-SWEDD group was done due to the large difference of the subject numbers. Striatal SBR values and striatal asymmetry indices were significantly different (p < 0.001) between the two groups at both baseline and after 2 years, but there were no significant difference with respect to the MDS-UPDRS III scores after 2 years between the two groups. CONCLUSION: The different SBR values and asymmetry indices between the PD and PD-SWEDD groups at baseline and after 2 years indicate that SWEDD may not be early PD, but rather a different disease entity.
Authors: Kenneth Marek; John Seibyl; Shirley Eberly; David Oakes; Ira Shoulson; Anthony E Lang; Chris Hyson; Danna Jennings Journal: Neurology Date: 2014-04-23 Impact factor: 9.910
Authors: Christopher H van Dyck; John P Seibyl; Robert T Malison; Marc Laruelle; Sami S Zoghbi; Ronald M Baldwin; Robert B Innis Journal: Am J Geriatr Psychiatry Date: 2002 Jan-Feb Impact factor: 4.105
Authors: Fabienne S Sprenger; Klaus Seppi; Atbin Djamshidian; Eva Reiter; Michael Nocker; Katherina Mair; Georg Göbel; Werner Poewe Journal: Mov Disord Date: 2015-03-15 Impact factor: 10.338
Authors: G Webster Ross; Helen Petrovitch; Robert D Abbott; James Nelson; William Markesbery; Daron Davis; John Hardman; Lenore Launer; Kamal Masaki; Caroline M Tanner; Lon R White Journal: Ann Neurol Date: 2004-10 Impact factor: 10.422
Authors: L Silveira-Moriyama; P Schwingenschuh; A O'Donnell; S A Schneider; P Mir; F Carrillo; C Terranova; A Petrie; D G Grosset; N P Quinn; K P Bhatia; A J Lees Journal: J Neurol Neurosurg Psychiatry Date: 2009-03-09 Impact factor: 10.154
Authors: Marco J Russo; Christina D Orru; Luis Concha-Marambio; Simone Giaisi; Bradley R Groveman; Carly M Farris; Bret Holguin; Andrew G Hughson; David-Erick LaFontant; Chelsea Caspell-Garcia; Christopher S Coffey; Jennifer Mollon; Samantha J Hutten; Kalpana Merchant; Roland G Heym; Claudio Soto; Byron Caughey; Un Jung Kang Journal: Acta Neuropathol Commun Date: 2021-11-06 Impact factor: 7.801